Lung Diseases: Clinical Trials

1,934 trials for Lung Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1145 completed, 311 unknown, 183 terminated, 111 recruiting. 1934 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 41934Completed 1145, Unknown 311, Terminated 183, Recruiting 111, Withdrawn 83, Not yet recruiting 52, Active not recruiting 38, Suspended 6, Enrolling by invitation 5

Follow Lung Diseases: new trials by email Literature Review of Lung Diseases trials Research Report on Lung Diseases

Trials (filtered) newest first · largest first

All 1,934 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RSV Vaccination to Reduce Recurrent AECOPD
RSV vaccination (Arexvy, GlaxoSmithKline) - COPD, RSV
Phase 4Not yet recruitingChinese University of Hong Kong3202027-07-012026-04-13
Prevent Wheeze Trial
Dexamethasone 0.6 mg/kilogram body weight single dose, Placebo - Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing
Phase 4Not yet recruitingNorwegian University of Science and Technology4862027-02-012026-10-05
Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype
Roflumilast Oral Tablet, Azithromycin 250 mg - Chronic Obstructive Pulmonary Disease With Exacerbation
Phase 4Not yet recruitingSidra Aziz702027-02-012026-08-31
The LalelaLung Study: Digital Stethoscope Clinical Evaluation
StethoMe AI-enabled digital stethoscope system, Standard IMCI assessment - Pneumonia, Tuberculosis, Pulmonary
Phase 4Not yet recruitingJohns Hopkins University3502026-12-072026-11-10
Effect of add-on Doxofylline on Lung Function in Stable COPD
Doxofylline - Chronic Obstructive Pulmonary Disease
Phase 4Not yet recruitingUniversity of Milan782026-12-012026-04-29
A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)
Sotatercept - Hypertension, Pulmonary
Phase 4Not yet recruitingMerck Sharp & Dohme LLC402026-11-302026-10-28
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
Belumosudil - Chronic Graft Versus Host Disease
Phase 4Not yet recruitingSanofi262026-11-202026-11-10
CYTALUX Dose Extension Study
CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer
Phase 4Not yet recruitingOn Target Laboratories, LLC1062026-11-152026-11-09
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
edoxaban, Apixaban - Venous Thromboembolism, Active Cancer
Phase 4Not yet recruitingSamsung Medical Center23002026-11-012026-10-01
Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate
Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash - Asthma
Phase 4Not yet recruitingUniversity of Wisconsin, Madison202026-11-012026-11-05
Iron Repletion in Cystic Fibrosis
IV Repletion, PO Repletion - Cystic Fibrosis, Iron Deficiencies
Phase 4Not yet recruitingUniversity of Michigan1002026-11-012026-10-29
Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)
Dopamine administration, Norepinephrine - Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN)
Phase 4RecruitingUniversity of California, Davis302026-10-302026-08-18
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
mRNA-1273, mRNA-1283 - SARS-CoV-2
Phase 4RecruitingModernaTX, Inc.6002026-10-092026-11-04
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Sotatercept, Background PAH Therapy - Pulmonary Arterial Hypertension
Phase 4RecruitingMerck Sharp & Dohme LLC302026-10-082026-11-04
Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
Gabapentin, Benzonatate 200 mg, Standard of care treatment for ILD - Interstitial Lung Disease
Phase 4Not yet recruitingPost Graduate Institute of Medical Education and Research, Chandigarh1772026-10-072026-10-08
Tobramycin Nebulization to Prevent Multidrug-Resistant Ventilator-Associated Pneumonia
Tobramycin inhalation solution, 0.9% Sodium Chloride Placebo - Pneumonia, Ventilator-Associated
Phase 4Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine5742026-10-072026-10-02
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
dupilumab, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 4RecruitingRegeneron Pharmaceuticals7542026-10-062026-10-16
Airway Dysfunction, Occlusions and Remodeling: COPD Patients and Mepolizumab
Mepolizumab 100 MG Injection - COPD (Chronic Obstructive Pulmonary Disease)
Phase 4Not yet recruitingWestern University, Canada362026-10-012026-08-06
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
Selpercatinib - Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 4Not yet recruitingEli Lilly and Company302026-10-012026-10-08
Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion
Glycerol Guiacolate, SOC (Standard of care) - Bronchitis, Bronchitis, Chronic
Phase 4Not yet recruitingUniversity of North Carolina, Chapel Hill402026-10-012026-10-14

Showing 20 of 1934. Sign in to see all of them.

Narrower conditions

Asthma (430)  ·  Pulmonary Disease, Chronic Obstructive (430)  ·  COVID-19 (243)  ·  Pneumonia (108)  ·  Carcinoma, Non-Small-Cell Lung (91)  ·  Cystic Fibrosis (88)  ·  Lung Neoplasms (73)  ·  Hypertension, Pulmonary (69)  ·  Pulmonary Embolism (69)  ·  Pulmonary Arterial Hypertension (63)  ·  Bronchiolitis Obliterans Syndrome (53)  ·  Respiratory Distress Syndrome (46)  ·  Pneumonia, Ventilator-Associated (37)  ·  Bronchitis, Chronic (33)

Broader conditions

Respiratory Tract Diseases (1920)  ·  Lung Diseases, Obstructive (919)  ·  Pathological Conditions, Signs and Symptoms (716)  ·  Pathologic Processes (633)  ·  Bronchial Diseases (566)  ·  Disease Attributes (537)  ·  Immune System Diseases (537)  ·  Infections (521)  ·  Respiratory Tract Infections (495)  ·  Chronic Disease (468)  ·  Hypersensitivity (447)  ·  Hypersensitivity, Immediate (440)  ·  Respiratory Hypersensitivity (431)  ·  Pneumonia (303)

Interventions

Fluticasone (80)  ·  Tiotropium Bromide (75)  ·  Budesonide (69)  ·  Albuterol (66)  ·  Salmeterol Xinafoate (58)  ·  Formoterol Fumarate (55)  ·  montelukast (48)  ·  Fluticasone-Salmeterol Drug Combination (46)  ·  Saline Solution (35)  ·  Azithromycin (32)  ·  Dexamethasone (27)  ·  Sodium Chloride (27)  ·  Budesonide, Formoterol Fumarate Drug Combination (26)  ·  Omalizumab (26)  ·  Standard of Care (25)

Sponsors

GlaxoSmithKline (92)  ·  AstraZeneca (51)  ·  Novartis Pharmaceuticals (47)  ·  Boehringer Ingelheim (43)  ·  Organon and Co (19)  ·  University of Dundee (19)  ·  Sanofi (16)  ·  University of Zurich (16)  ·  Actelion (13)  ·  United Therapeutics (13)  ·  China National Biotec Group Company Limited (12)  ·  Imperial College London (12)  ·  Pfizer (12)  ·  University of Saskatchewan (12)  ·  Assistance Publique - Hôpitaux de Paris (11)

Countries

United States (555)  ·  China (202)  ·  Canada (148)  ·  United Kingdom (145)  ·  Germany (122)  ·  Spain (120)  ·  France (112)  ·  Netherlands (100)  ·  Italy (94)  ·  Denmark (86)  ·  Belgium (76)  ·  Brazil (60)  ·  Poland (57)  ·  Sweden (45)  ·  Russia (44)

Top investigators

Konrad E Bloch, MD (13)  ·  Talant M Sooronbaev, MD (10)  ·  Brian Lipworth, MD (6)  ·  Don Cockcroft, MD (6)  ·  Iwona Stelmach, MD, PhD, Prof (6)  ·  Manana Tchaia, MD (6)  ·  Merab Lomia, MD, PhD (6)

Results publications

PMID 35244208, PMID 34473343, PMID 33502773, PMID 37591523, PMID 11019457, PMID 16322646, PMID 16799080, PMID 17310045, PMID 17872488, PMID 17951621, PMID 18625750, PMID 18804362, PMID 19897551, PMID 20167147, PMID 21428765, PMID 23613569, PMID 26026936, PMID 26351971, PMID 27449641, PMID 27883002, PMID 29531764, PMID 29763572, PMID 30237305, PMID 32043986, PMID 32298853, PMID 33369570, PMID 33735508, PMID 34061144, PMID 34433773, PMID 34611902, PMID 35012490, PMID 35048355, PMID 36053283, PMID 36472162, PMID 36625789, PMID 36658045, PMID 37230961, PMID 37347518, PMID 37489818, PMID 37536444, PMID 37952772, PMID 38990335, PMID 39756820, PMID 40920961, PMID 8810608, PMID 10109801, PMID 10221490, PMID 10404452, PMID 10430726, PMID 10735670

NIH funding

2017 (20), 2019 (18), 2015 (15), 2025 (13), 2016 (12), 2023 (11), 2014 (10), 2018 (8), 2009 (5), 2005 (3), 2004 (2), 2008 (2), R01AT007987 (2), 1OT2HL156812-01 (1), K23GM112014 (1)